Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M331Revenue $M63.4Net Margin (%)-44.0Altman Z-Score-2.3
Enterprise Value $M242EPS $-0.2Operating Margin %-32.8Piotroski F-Score5
P/E(ttm)--Beneish M-Score11.6Pre-tax Margin (%)-44.0Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %-26.9Quick Ratio5.0Cash flow > EarningsY
Price/Sales5.25-y EBITDA Growth Rate %-23.2Current Ratio5.2Lower Leverage y-yY
Price/Free Cash Flow6.3y-y EBITDA Growth Rate %--ROA % (ttm)-15.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-291.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M125ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 2.75-27%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 2.75-12%New holding500,000
OREXFirst Eagle Investment 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 2.75-45%Sold Out0
OREXFirst Eagle Investment 2010-06-30 Add$4.05 - $7.04
($5.57)
$ 2.75-51%Add 74.07%470,000
OREXFirst Eagle Investment 2010-03-31 Add$5.9 - $7.66
($6.55)
$ 2.75-58%Add 22.73%270,000
OREXFirst Eagle Investment 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 2.75-64%Add 83.33%220,000
OREXFirst Eagle Investment 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 2.75-65%New holding120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
($3.19)
$ 2.75-14%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Booth Mark DChief Commercial Officer 2015-02-26Sell50,000$5.68-51.58view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$6-54.17view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.83-52.83view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.58-50.72view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.57-50.63view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.47-38.48view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.78-42.47view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.69-41.36view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-64.74view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-63.58view

Quarterly/Annual Reports about OREX:

News about OREX:

Articles On GuruFocus.com
Oxford Industries (OXM) Solid Growth Metrics, Orexigen Therapeutics (OREX) European Anti-Obesity App Mar 27 2015 
Orexigen Therapeutics' Bright Future Mar 03 2015 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 21 2015
How the bulls are playing Orexigen Aug 21 2015
OREXIGEN THERAPEUTICS, INC. Financials Aug 18 2015
10-Q for Orexigen Therapeutics, Inc. Aug 09 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2015
Orexigen 2Q Loss Wider Than Expected, Settles with Takeda - Analyst Blog Aug 07 2015
Edited Transcript of OREX earnings conference call or presentation 6-Aug-15 12:00pm GMT Aug 06 2015
Orexigen Therapeutics Inc Earnings Call scheduled for 8:00 am ET today Aug 06 2015
Orexigen reports 2Q loss Aug 06 2015
Orexigen reports 2Q loss Aug 06 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results... Aug 06 2015
Q2 2015 Orexigen Therapeutics Inc Earnings Release - Before Market Open Aug 06 2015
Orexigen Therapeutics Reports Financial and Business Results for the Second Quarter Ended June 30,... Aug 06 2015
Orexigen Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical Company Aug 06 2015
Orexigen and Takeda Announce an Amended and Restated Collaboration Agreement Aug 06 2015
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2015 Financial Results... Jul 24 2015
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 26 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK